Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261]

The availability of antitumor cytotoxic T lymphocytes which can be generated from either peripheral blood lymphocytes after stimulation in vitro or tumor infiltrating lymphocytes (TIL) has made it possible to identify a number of melanoma antigens presented by major histocompatibility complex class I molecules. The present and previous studies indicated that TIL586 recognized an antigen expressed on most melanoma and normal melanocytes in the context of the HLA-A31 molecule. We report here the cloning of a cDNA that directs the expression of the shared melanoma antigen recognized by this TIL. The DNA sequence analysis revealed that the cDNA was almost identical to the gene encoding tyrosinase-related protein 1 or glycoprotein gp75 which was originally identified by serum antibodies in a patient with melanoma. The gene was found to be expressed only in melanoma, normal melanocyte cell lines, and retina, but not in other normal tissues tested. The gp75 antigen presented by HLA-A31 may therefore constitute a useful immune target for specific treatment of patients with melanoma, since both antibody- and T cell-mediated immune responses can be generated against this antigen.

[1]  S. Rosenberg,et al.  Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.

[2]  C. Figdor,et al.  Molecular characterization of the melanocyte lineage-specific antigen gp100. , 1994, The Journal of biological chemistry.

[3]  K. Urabe,et al.  A new enzymatic function in the melanogenic pathway. The 5,6-dihydroxyindole-2-carboxylic acid oxidase activity of tyrosinase-related protein-1 (TRP1). , 1994, The Journal of biological chemistry.

[4]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[6]  F. Marincola,et al.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[7]  A. Houghton.  Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.

[8]  S. Rosenberg,et al.  Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.

[9]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[11]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[12]  P. Coulie,et al.  Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. , 1994, Important advances in oncology.

[13]  G. Parmiani,et al.  Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. , 1993, Immunology today.

[14]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[15]  R. Halaban,et al.  White mutants in mice shedding light on humans. , 1993, The Journal of investigative dermatology.

[16]  J. Richards,et al.  Sequential chemoimmunotherapy in the treatment of metastatic melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Houghton,et al.  Assignment of the human TYRP (brown) locus to chromosome region 9p23 by nonradioactive in situ hybridization. , 1992, Genomics.

[18]  S. Rosenberg,et al.  Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Copeland,et al.  A second tyrosinase‐related protein, TRP‐2, maps to and is mutated at the mouse slaty locus. , 1992, The EMBO journal.

[20]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[21]  D. Barton,et al.  A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Rosenberg,et al.  Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[23]  S. Shibahara,et al.  Nucleotide sequence of the cDNA encoding human tyrosinase-related protein. , 1990, Nucleic acids research.

[24]  P. Parham,et al.  Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Slingluff,et al.  Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. , 1990, Cancer research.

[26]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[27]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[28]  C. Balch,et al.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor , 1988, The Journal of experimental medicine.

[29]  I. Jackson,et al.  A cDNA encoding tyrosinase-related protein maps to the brown locus in mouse. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Linehan,et al.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Real,et al.  Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. , 1988, The Journal of investigative dermatology.

[32]  A. Kopf,et al.  Prognostic significance of hypopigmentation in malignant melanoma. , 1987, Archives of dermatology.

[33]  R. Devos,et al.  Production of stable cytolytic T‐cell clones directed against autologous human melanoma , 1987, International journal of cancer.

[34]  L. Old,et al.  A pigmentation‐associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum , 1983, International journal of cancer.

[35]  J. Kirkwood,et al.  Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.